A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

8K views

⸱

DOI:

10.3791/52574

⸱

March 30th, 2015

 ,  ,  ,  ,  ,  ,  ,  ,  , 

In This Article

Summary

Optical coherence tomography (OCT) is a high resolution imaging technique that allows analysis of tissue specific optical properties providing the means for tissue differentiation. We developed needle based OCT, providing real-time imaging combined with on-the-spot tumor differentiation. This publication describes a method for percutaneous, needle based OCT of renal masses.

Abstract

Optical coherence tomography (OCT) is the optical equivalent of ultrasound imaging, based on the backscattering of near infrared light. OCT provides real time images with a 15 µm axial resolution at an effective tissue penetration of 2-3 mm. Within the OCT images the loss of signal intensity per millimeter of tissue penetration, the attenuation coefficient, is calculated. The attenuation coefficient is a tissue specific property, providing a quantitative parameter for tissue differentiation.

Until now, renal mass treatment decisions have been made primarily on the basis of MRI and CT imaging characteristics, age and comorbidity. However these parameters and diagnostic methods lack the finesse to truly detect the malignant potential of a renal mass. A successful core biopsy or fine needle aspiration provides objective tumor differentiation with both sensitivity and specificity in the range of 95-100%. However, a non-diagnostic rate of 10-20% overall, and even up to 30% in SRMs, is to be expected, delaying the diagnostic process due to the frequent necessity for additional biopsy procedures.

We aim to develop OCT into an optical biopsy, providing real-time imaging combined with on-the-spot tumor differentiation. This publication provides a detailed step-by-step approach for percutaneous, needle based, OCT of renal masses.

Introduction

The past decades have shown a steady increase in the incidence of renal masses 1,2. Until now, renal mass treatment decisions have been made primarily on the basis of MRI and CT imaging characteristics, age and comorbidity. However these diagnostic methods and clinical parameters lack the finesse to truly detect the malignant potential of a renal mass. A core biopsy or fine needle aspiration with sufficient tissue for pathological evaluation (diagnostic) provides objective tumor differentiation with both sensitivity and specificity in the range of 95-100% 3. Therefore biopsy is gaining acceptance in the evaluation of suspicious renal masses ....

Access restricted. Please log in or start a trial to view this content.

Protocol

The presented procedure takes place under a research protocol approved by the Institutional Review Board of the Academic Medical Center Amsterdam, registration number NL41985.018. Written informed consent is required from all participants.

1. System

  1. For this experiment, use a Fourier domain OCT system, operating at a 1,280–1,350 nm wavelength band 13. Fourier domain low-coherence interferometry allows for continuous scanning which increases the data acquisition speed when compared to the first generation time-domain OCT systems. Note: The OCT system is interfaced with a fiber optic probe, scanning helically at ~....

Access restricted. Please log in or start a trial to view this content.

Results

Among the first 25 tumors (23 patients), a total of 24 successful OCT procedures were performed. In one case a probe malfunction led to the inability to acquire an OCT scan. Two adverse events (AE) occurred, which are described in detail in the discussion section. General patient characteristics are found in Table 1.

The OCT console has pre-installed software providing real-time OCT images for immediate qualitative analysis of acquired datasets. For further analysis and attenu.......

Access restricted. Please log in or start a trial to view this content.

Discussion

In this publication we report on the feasibility of percutaneous, needle based, OCT of the kidney. This is an essential first step in the development of OCT into a clinically applicable technique for tumor differentiation, termed as an “Optical Biopsy”. Our first 25 patients have shown percutaneous OCT to be an easy and safe procedure. An optical biopsy has two advantages over conventional core biopsies. First, the real time acquisition and analysis of OCT data will provide instant diagnostic results, compare.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors of this article have nothing to disclose.

Acknowledgements

This work is funded by the Cure for Cancer Foundation, Dutch Technology Foundation (STW) and The Netherlands Organisation for Health Research and Development (ZonMw).

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
15 G/7.5 cm Co-Axial Introducer NeedleAngiotech, Gainesville, USAMCXS1612SX
18 G/20 cm Trocar NeedleCook medical, Bloomington, USADTN-18-20.0-U
16 G/20 cm Quick-Core Biopsy GunCook Medical, Bloomington, USAG07827
Ilumien Optis PCI Optimization System (OCT & FFR)St. Jude medical, St. Paul, USAC408650Part of Dragonfly Kit.
St. Jude medical, St. Paul, USA. (C4088643)
Dragonfly Duo Imaging CatheterLightLab Imaging, Westford, USAC408644Part of Dragonfly Kit.
St. Jude medical, St. Paul, USA. (C4088643)
Sterile Dock CoverCFI Med. Solutions, Fenton, USA200-700-00Part of Dragonfly Kit.
St. Jude medical, St. Paul, USA. (C4088643)
5 ml Luer-lock SyringeMerit Med. Syst., South Jordan, USAC408647
10 ml SyringeBD, Franklin Lakes, USA300912
18 G Blunt Fill NeedleBD, Franklin Lakes, USA305180
21 G Injection NeedleBD, Franklin Lakes, USA301155
Sterile scalpelBD, Franklin Lakes, USA372611
NaCl 0,9% solutionBraun, Melsungen AG, Germany222434
Lidocaïne HCl 2% (20 mg/ml) solutionBraun, Melsungen AG, Germany3624480
Sterile Ultrasound Gel, Aquasonic 100Parker Lab. Inc., Fairfield, USAGE424609
Sterile Ultrasound CoverMicrotek Med., Alpharetta, USAPC1289EU
Pathology Container
AMIRA software packageFEI Visualization Sciences Group, Hillsboro, USASoftware platform for 3D data analysis
FIJI software package (open source)Open source, http://fiji.sc/FijiOpen source image processing software

References

  1. Jemal, A., Siegel, R., Xu, J., Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
  2. Mathew, A., Devesa, S. S., Fraumeni, J. F., Chow, W. H. Global increases in kidney cancer incidence, 1973-1992. Eur. J. Cancer Prev. 11, 171-178 (2002).
  3. Volpe, A., et al. <....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Renal Mass ImagingTumor DifferentiationAttenuation CoefficientUltrasound GuidanceCore BiopsyDragonfly Duo ProbeAmira SoftwareFiji Analysis